# CIBILTECH

PROBLEM

Chronic Kidney Disease (CKD) is one of the leading causes of public health issues worldwide (prevalence of 13.4%). CKD is characterized by gradual loss of kidney function, leading to end-stage renal disease (ESRD). ESRD requires renal replacement therapy in the form of dialysis or kidney transplantation.

Long-term allograft outcome and allograft rejection remains the major causes of graft loss. After 5 years, 1 out of 5 patients will lose their transplant and after 10 years, it is 1 out of 2. These patients will go back to dialysis with a major toll on their quality of life, life expectancy and this is extremely expensive.

iBox Graft survival probability evolution since the last biopsy

> " The DigitalHealth.London Accelerator programme truly provides tailor-made support. The team has supported us to strengthen our evidence from the CIBIL trial with a real world evidence pilot study and to demonstrate the savings Predigraft could achieve for the NHS by reducing patients returning to dialysis. "

SUCCESSES AND IMPACT

- Recently the first patient in the UK has been enrolled to the International CIBIL clinical trial. Cibiltech has successfully recruited 2267 patients so far, with 8 actively recruiting sites in 4 countries. In total, 18 centres in 7 countries will participate in this international study.

- New medical devices implementation in Europe is contingent upon obtaining CE marking. Cibiltech was the first French digital start-up to obtain CE marking under the new European MDR regulation for its Predigraft software, and now extends this certification to its Apilife telemonitoring Software

- The iBox system has been qualified by the European Medicines Agency (EMA). It is a major and unprecedented achievement in medicine that a multimodal predictive algorithm of a hard end-point receives qualification by the EMA. This is a significant milestone in the adoption and use of iBox technology.

80% strong long-term kidney allograft survival prediction capacity with a concordance statistic

**40%** retention rate of users with the app after 2 months

2300 patients using application in France

Find out more:

SOLUTION

Cibiltech's objective is to improve patient quality of life by increasing transplant survival. Based on a predictive algorithm, they developed a telemonitoring platform for kidney transplanted patients to prevent organ failures. By detecting graft abnormalities earlier, Predigraft could drive an anticipated personalised medical treatment, thus avoiding return on dialysis.

> " Predigraft has the potential to be a valuable platform for integrated care of our kidney transplant patients, with iBox risk modelling embedded to guide clinical decision-making, that we hope can ultimately improve long-term outcomes. "
>
> *- Dr Adnan Sharif*

WHAT'S NEXT?

Cibiltech's objective is to carry out their international multicenter randomised controlled trial in 18 centres and 7 countries and deploy the solutions in these countries in order to gather clinical health economics evidence on Predigraft benefits. In parallel, they work on a global platform solution dedicated to global chronic diseases.